Chongqing Pharscin Pharmaceutical announced that the company recently learned from the website of the National Medical Products Administration (NMPA) that the company's pharmaceutical product Injection of Glycyrrhetinic Acid Diammonium has completed the domestic drug registration for the newly added production site and updated production company name or address, and the registration information has been publicly displayed on the NMPA website.
华森制药：品注射用甘草酸二铵完成境内生产药品备案
Chongqing Pharscin Pharmaceutical: pharmaceutical injection of dipotassium glycyrrhizinate completes domestic drug production filing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.